phone

Anthrax - Pipeline Review, H2 2017

  • Published Date: 18 Jul 2017
  • Number of Pages: 142
  • Category: Pharmaceuticals
  • Country: Global
Anthrax - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Pipeline Review, H2 2017, provides an overview of the Anthrax (Infectious Disease) pipeline landscape.

Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Anthrax - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 24 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anthrax (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Anthrax (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anthrax (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anthrax (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anthrax (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

Introduction 7
Global Markets Direct Report Coverage 7
Anthrax - Overview 8
Anthrax - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 17
Anthrax - Therapeutics Assessment 18
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Anthrax - Companies Involved in Therapeutics Development 26
Altimmune Inc 26
Aphios Corp 26
Aradigm Corp 27
Companhia Industrial Produtora de Antibioticos SA 27
ContraFect Corp 28
Crestone Inc 28
Dynavax Technologies Corp 29
Emergent BioSolutions Inc 29
GlaxoSmithKline Plc 30
Green Cross Corp 30
Grifols SA 31
Hawaii Biotech Inc 31
iBio Inc 32
Merck & Co Inc 32
Microbiotix Inc 33
NanoBio Corp 33
PaxVax Inc 34
Pfenex Inc 34
Protein Potential LLC 35
ProThera Biologics Inc 35
Soligenix Inc 36
Syntiron LLC 36
Tetraphase Pharmaceuticals Inc 37
VLP Biotech Inc 37
Anthrax - Drug Profiles 38
anthrax (virus like particles) vaccine - Drug Profile 38
anthrax + plague vaccine - Drug Profile 39
anthrax vaccine - Drug Profile 40
anthrax vaccine - Drug Profile 42
anthrax vaccine - Drug Profile 43
anthrax vaccine - Drug Profile 44
anthrax vaccine - Drug Profile 45
anthrax vaccine - Drug Profile 46
Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax - Drug Profile 47
ARD-3100 - Drug Profile 48
AV-7909 - Drug Profile 52
BDM-I - Drug Profile 55
CF-306 - Drug Profile 58
CF-307 - Drug Profile 59
CF-308 - Drug Profile 60
ciprofloxacin hydrochloride - Drug Profile 61
CPN-1311 - Drug Profile 62
DPX-Anthrax - Drug Profile 63
DV-230 - Drug Profile 66
epimerox - Drug Profile 67
EV-035 - Drug Profile 68
GC-1109 - Drug Profile 70
gepotidacin mesylate - Drug Profile 71
GREANX - Drug Profile 74
KKL-35 - Drug Profile 75
Marinus - Drug Profile 76
Monoclonal Antibody for Anthrax - Drug Profile 77
Monoclonal Antibody for Anthrax - Drug Profile 78
Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile 79
Nasoshield - Drug Profile 80
PBI-220 - Drug Profile 82
Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile 84
Protein to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 85
Px-563L - Drug Profile 87
Px-563L Second Generation - Drug Profile 89
raxibacumab - Drug Profile 90
Recombinant Proteins for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and Anthrax - Drug Profile 91
RiVax + SGX-204 - Drug Profile 92
rPA-01 - Drug Profile 93
RPA-563 - Drug Profile 94
Small Molecules for Bacterial Infections, Skin Infections and Bone Disorders - Drug Profile 95
Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax - Drug Profile 96
Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile 97
Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile 99
Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile 100
solithromycin - Drug Profile 101
SparVax - Drug Profile 115
TP-271 - Drug Profile 120
Anthrax - Dormant Projects 123
Anthrax - Discontinued Products 126
Anthrax - Product Development Milestones 127
Featured News & Press Releases 127
Appendix 138
Methodology 138
Coverage 138
Secondary Research 138
Primary Research 138
Expert Panel Validation 138
Contact Us 138
Disclaimer 139

List Of Tables


Number of Products under Development for Anthrax, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Anthrax - Pipeline by Altimmune Inc, H2 2017
Anthrax - Pipeline by Aphios Corp, H2 2017
Anthrax - Pipeline by Aradigm Corp, H2 2017
Anthrax - Pipeline by Companhia Industrial Produtora de Antibioticos SA, H2 2017
Anthrax - Pipeline by ContraFect Corp, H2 2017
Anthrax - Pipeline by Crestone Inc, H2 2017
Anthrax - Pipeline by Dynavax Technologies Corp, H2 2017
Anthrax - Pipeline by Emergent BioSolutions Inc, H2 2017
Anthrax - Pipeline by GlaxoSmithKline Plc, H2 2017
Anthrax - Pipeline by Green Cross Corp, H2 2017
Anthrax - Pipeline by Grifols SA, H2 2017
Anthrax - Pipeline by Hawaii Biotech Inc, H2 2017
Anthrax - Pipeline by iBio Inc, H2 2017
Anthrax - Pipeline by Merck & Co Inc, H2 2017
Anthrax - Pipeline by Microbiotix Inc, H2 2017
Anthrax - Pipeline by NanoBio Corp, H2 2017
Anthrax - Pipeline by PaxVax Inc, H2 2017
Anthrax - Pipeline by Pfenex Inc, H2 2017
Anthrax - Pipeline by Protein Potential LLC, H2 2017
Anthrax - Pipeline by ProThera Biologics Inc, H2 2017
Anthrax - Pipeline by Soligenix Inc, H2 2017
Anthrax - Pipeline by Syntiron LLC, H2 2017
Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017
Anthrax - Pipeline by VLP Biotech Inc, H2 2017
Anthrax - Dormant Projects, H2 2017
Anthrax - Dormant Projects, H2 2017 (Contd..1), H2 2017
Anthrax - Dormant Projects, H2 2017 (Contd..2), H2 2017
Anthrax - Discontinued Products, H2 2017

List Of Figures


Number of Products under Development for Anthrax, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

Anthrax - Pipeline Review, H2 2017 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Pipeline Review, H2 2017, provides an overview of the Anthrax (Infectious Disease) pipeline

View Report

Anthrax Global Clinical Trials Review, H1, 2017 GlobalDatas clinical trial report, Anthrax Global Clinical Trials Review, H1, 2017 provides an overview of Anthrax clinical trials scenario. This report provides top line

View Report

Anthrax -Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Anthrax. The key objective of the report is to establish the understanding for all the pipeline

View Report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports